Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium-assisted vonoprazan quadruple therapy for refractory Helicobacter pylori infection
ChiCTR2400090233Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Golden Bifid in Helicobacter pylori infection and Refractory Helicobacter pylori infection (2 arms), sponsored by Tongji Hospital. Primary endpoints: Helicobacter pylori eradication rate and Adverse events. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
Golden Bifid
03
Conditions
Helicobacter pylori infectionRefractory Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400090233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090233.